Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  3/13/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 3/13/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  3/13/2018
Yale University
mi
from
New Haven, CT
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 3/13/2018
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  3/13/2018
Baptist MD Anderson Cancer Center
mi
from
Jacksonville, FL
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 3/13/2018
Baptist MD Anderson Cancer Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  3/13/2018
Beth Israel Deaconness Medical Center
mi
from
Boston, MA
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 3/13/2018
Beth Israel Deaconness Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  3/13/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 3/13/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  3/13/2018
University Hospitals
mi
from
Cleveland, OH
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 3/13/2018
University Hospitals
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  3/13/2018
Providence Cancer Center Oncology and Hematology Care Eastside, Site #194
mi
from
Portland, OR
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 3/13/2018
Providence Cancer Center Oncology and Hematology Care Eastside, Site #194
mi
from
Portland, OR
Click here to add this to my saved trials
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  3/13/2018
Lehigh Valley Health Network
mi
from
Allentown, PA
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 3/13/2018
Lehigh Valley Health Network
mi
from
Allentown, PA
Click here to add this to my saved trials
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  3/13/2018
Georgetown University Medical Center
mi
from
Washington,
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 3/13/2018
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  3/13/2018
MedStar Washington Hospital Center
mi
from
Washington,
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 3/13/2018
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
A Phase 2 Study of Capecitabine in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
Status: Enrolling
Updated:  3/15/2018
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
A Phase 2 Study of Capecitabine in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
Status: Enrolling
Updated: 3/15/2018
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated:  3/21/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated: 3/21/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated:  3/21/2018
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated: 3/21/2018
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated:  3/21/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated: 3/21/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated:  3/21/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated: 3/21/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated:  3/21/2018
Northwestern Memorial Hospital
mi
from
Chicago, IL
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated: 3/21/2018
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated:  3/21/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated: 3/21/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated:  3/21/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated: 3/21/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated:  3/21/2018
University of Wisconsin
mi
from
Madison, WI
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated: 3/21/2018
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated:  3/21/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated: 3/21/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated:  3/21/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated: 3/21/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated:  3/21/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Minimally Invasive Groin Dissection for Melanoma
Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
Status: Enrolling
Updated: 3/21/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Second Echelon Node Study With Methylene Blue
Feasibility of Lymphatic Mapping of Second Echelon Lymph Nodes With Methylene Blue
Status: Enrolling
Updated:  3/21/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
Second Echelon Node Study With Methylene Blue
Feasibility of Lymphatic Mapping of Second Echelon Lymph Nodes With Methylene Blue
Status: Enrolling
Updated: 3/21/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
Status: Enrolling
Updated:  3/21/2018
University of Pittsburgh Medical Center - Hillman Cancer Center
mi
from
Pittsburgh, PA
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
Status: Enrolling
Updated: 3/21/2018
University of Pittsburgh Medical Center - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Providence VA Medical Center, Providence, RI
mi
from
Providence, RI
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Providence VA Medical Center, Providence, RI
mi
from
Providence, RI
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA Palo Alto Health Care System, Palo Alto, CA
mi
from
Palo Alto, CA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA Palo Alto Health Care System, Palo Alto, CA
mi
from
Palo Alto, CA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA San Diego Healthcare System, San Diego, CA
mi
from
San Diego, CA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA San Diego Healthcare System, San Diego, CA
mi
from
San Diego, CA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA Eastern Colorado Health Care System, Denver, CO
mi
from
Denver, CO
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA Eastern Colorado Health Care System, Denver, CO
mi
from
Denver, CO
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Bay Pines VA Healthcare System, Pay Pines, FL
mi
from
Bay Pines, FL
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Bay Pines VA Healthcare System, Pay Pines, FL
mi
from
Bay Pines, FL
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Miami VA Healthcare System, Miami, FL
mi
from
Miami, FL
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Miami VA Healthcare System, Miami, FL
mi
from
Miami, FL
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Edward Hines Jr. VA Hospital, Hines, IL
mi
from
Hines, IL
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Edward Hines Jr. VA Hospital, Hines, IL
mi
from
Hines, IL
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Durham VA Medical Center, Durham, NC
mi
from
Durham, NC
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Durham VA Medical Center, Durham, NC
mi
from
Durham, NC
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Philadelphia VA Medical Center, Philadelphia, PA
mi
from
Philadelphia, PA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Philadelphia VA Medical Center, Philadelphia, PA
mi
from
Philadelphia, PA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
mi
from
Nashville, TN
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
mi
from
Nashville, TN
Click here to add this to my saved trials
Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma
Pilot Study to Identify Biomarkers That May Predict Response to High Dose IL-2
Status: Enrolling
Updated:  3/29/2018
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma
Pilot Study to Identify Biomarkers That May Predict Response to High Dose IL-2
Status: Enrolling
Updated: 3/29/2018
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
Dose-seeking and Efficacy Study of the Combination of the BRAF Inhibitor Vemurafenib and High-dose Interferon Alfa-2b for Therapy of Advanced Melanoma
Status: Enrolling
Updated:  4/1/2018
Hillman Cancer Center
mi
from
Pittsburgh, PA
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
Dose-seeking and Efficacy Study of the Combination of the BRAF Inhibitor Vemurafenib and High-dose Interferon Alfa-2b for Therapy of Advanced Melanoma
Status: Enrolling
Updated: 4/1/2018
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated:  4/2/2018
University of Michigan
mi
from
Ann Arbor, MI
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated: 4/2/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated:  4/2/2018
Oregon Health and Science University
mi
from
Portland, OR
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated: 4/2/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated:  4/2/2018
University of Texas Southwestern Medical Center Division of Hematology/Oncolog
mi
from
Dallas, TX
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated: 4/2/2018
University of Texas Southwestern Medical Center Division of Hematology/Oncolog
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated:  4/2/2018
Swedish Neuroscience Institute 550 17th Avenue, Suite 500
mi
from
Seattle, WA
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated: 4/2/2018
Swedish Neuroscience Institute 550 17th Avenue, Suite 500
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated:  4/2/2018
Novartis Investigative Site
mi
from
Caba,
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated: 4/2/2018
Novartis Investigative Site
mi
from
Caba,
Click here to add this to my saved trials
Interleukin-2 in Metastatic Melanoma
Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Melanoma
Status: Enrolling
Updated:  4/3/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Interleukin-2 in Metastatic Melanoma
Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Melanoma
Status: Enrolling
Updated: 4/3/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Green Tea Extract in Treating Patients With Actinic Keratosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology
Status: Enrolling
Updated:  4/3/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Green Tea Extract in Treating Patients With Actinic Keratosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology
Status: Enrolling
Updated: 4/3/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  4/5/2018
San Francisco Oncology Associates
mi
from
San Francisco, CA
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 4/5/2018
San Francisco Oncology Associates
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  4/5/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 4/5/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  4/5/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 4/5/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  4/5/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 4/5/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials